Alpha 2.0
Login Register
» Authors » W Hiddemann

W Hiddemann

Explore the profile of W Hiddemann including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 534
Citations 5788
Followers 0
Related Specialties
Oncology
Hematology
General Medicine
Top 10 Co-Authors
T Buchner
B Wormann
M Unterhalt
C Schoch
W Kern
W D Ludwig
T Haferlach
G Maschmeyer
J Braess
C Buske
Published In
Leukemia
Internist (Berl)
Dtsch Med Wochenschr
Ann Hematol
Ann Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
[The lung in systemic diseases : Between holistic and individualized medicine-a challenge for internal medicine]
Welte T, Vogelmeier C, Hiddemann W, Marker-Hermann E
Internist (Berl) . 2018 Aug; 59(9):873-875. PMID: 30143815
No abstract available.
2.
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Haubner S, Perna F, Kohnke T, Schmidt C, Berman S, Augsberger C, et al.
Leukemia . 2018 Jun; 33(1):64-74. PMID: 29946192
Targeted immunotherapy in acute myeloid leukemia (AML) is challenged by the lack of AML-specific target antigens and clonal heterogeneity, leading to unwanted on-target off-leukemia toxicity and risk of relapse from...
3.
[Paraneoplastic syndromes]
Hiddemann W, Reincke M
Internist (Berl) . 2018 Jan; 59(2):113. PMID: 29327270
No abstract available.
4.
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
Rothenberg-Thurley M, Amler S, Goerlich D, Kohnke T, Konstandin N, Schneider S, et al.
Leukemia . 2017 Dec; PMID: 29249818
Some patients with acute myeloid leukemia (AML) who are in complete remission after induction chemotherapy harbor persisting pre-leukemic clones, carrying a subset of leukemia-associated somatic mutations. There is conflicting evidence...
5.
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, et al.
Leukemia . 2017 Sep; 32(2):313-322. PMID: 28895560
The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but...
6.
[Internal emergency cases at the interface of outpatient and inpatient]
Buerke M, Hasenfuss G, Hiddemann W, Sieber C
Internist (Berl) . 2017 Aug; 58(9):881-882. PMID: 28828494
No abstract available.
7.
A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients
Beck D, Thoms J, Palu C, Herold T, Shah A, Olivier J, et al.
Leukemia . 2017 Jul; 32(2):263-272. PMID: 28674423
Prognostic gene expression signatures have been proposed as clinical tools to clarify therapeutic options in acute myeloid leukemia (AML). However, these signatures rely on measuring large numbers of genes and...
8.
Prof. Thomas Büchner (22 September 1934-5 August 2016)-A leading European hematologist and AML trialist
Berdel W, Hehlmann R, Hoelzer D, Hiddemann W
Leukemia . 2016 Sep; 30(11):2131-2132. PMID: 27609362
No abstract available.
9.
Reply to the letter to the editor 'the clinical dilemma of grade 3 follicular lymphoma' by Sorigue et al
Klapper W, Koch K, Hoster E, Schmitz N, Hiddemann W
Ann Oncol . 2016 Aug; 27(12):2303-2304. PMID: 27502720
No abstract available.
10.
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL
Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, et al.
Ann Oncol . 2016 Apr; 27(7):1323-9. PMID: 27117536
Background: Histologically, follicular lymphoma (FL) grades 1, 2 and 3A are composed of two distinct cell types, centroblasts and centrocytes. FL grade 3B is composed only of centroblasts and has...